Department of Psychiatry, Hospital Universitari Vall d'Hebron and Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
World J Biol Psychiatry. 2013 May;14(4):268-81. doi: 10.3109/15622975.2011.600333. Epub 2011 Nov 22.
Methylphenidate (MPH) is effective for adults with attention-deficit/hyperactivity disorder (ADHD). This study aimed to evaluate the efficacy and safety of OROS MPH in adults with ADHD.
Randomized, double-blind study; 279 subjects received OROS MPH 54 or 72 mg/day, or placebo, for 13 weeks. Primary endpoint was the Conners' Adult ADHD Rating Scale - Screening Version (CAARS-O:SV). Secondary outcomes included CAARS Self Report - Short Version (CAARS-S:S), Sheehan Disability Scale (SDS) and ADHD Impact Module - Adult (AIM-A).
Improvements in CAARS-O:SV were significantly greater with OROS MPH 72 mg vs. placebo (P = 0.0024). CAARS-S:S scores decreased significantly vs. placebo in both OROS MPH arms (P < 0.05). There was no significant change in SDS score from baseline in either treatment arm, although significant benefit vs. placebo was observed on several AIM-A subscales. Treatment was well tolerated.
OROS MPH provided overall benefits in the treatment of adults with ADHD.
哌醋甲酯（MPH）对成人注意缺陷多动障碍（ADHD）有效。本研究旨在评估控释哌甲酯（OROS MPH）治疗成人 ADHD 的疗效和安全性。
随机、双盲研究；279 名受试者接受 OROS MPH 54 或 72mg/天或安慰剂治疗 13 周。主要终点为 Conners 成人 ADHD 评定量表-筛查版（CAARS-O:SV）。次要结局包括 CAARS 自评量表-短版（CAARS-S:S）、Sheehan 残疾量表（SDS）和成人 ADHD 影响量表-模块（AIM-A）。
与安慰剂相比，OROS MPH 72mg 组的 CAARS-O:SV 改善显著更大（P=0.0024）。与安慰剂相比，OROS MPH 两组的 CAARS-S:S 评分均显著降低（P<0.05）。在任何治疗组中，SDS 评分从基线开始均无显著变化，但在几个 AIM-A 子量表上观察到与安慰剂相比有显著获益。治疗耐受性良好。
OROS MPH 为成人 ADHD 的治疗提供了整体获益。
